Gilead Sciences (GILD) stock closed down 0.57%, outperforming Medical sector, trailing S&P 500.

From Nasdaq: 2024-12-13 17:50:06

Gilead Sciences (GILD) closed trading at $91.86, down 0.57%. The Dow fell 0.2%, while the Nasdaq rose 0.12%. GILD’s shares have increased by 0.29% in the last month, outperforming the Medical sector but trailing the S&P 500.

Analysts expect GILD to report earnings of $1.67 per share, a 2.91% decrease YoY, with revenue of $7.05 billion, down 0.89%. Full-year estimates predict earnings of $4.36 per share and revenue of $28.23 billion.

GILD’s Zacks Rank of #3 (Hold) reflects recent EPS estimate changes. The stock’s Forward P/E ratio is 21.18, lower than the industry average of 23.1. The PEG ratio is 2.25, higher than the industry’s average of 1.83.

The Medical – Biomedical and Genetics industry ranks in the top 27% of all industries, with a Zacks Industry Rank of 67. Industry metrics and stock-moving data can be tracked on Zacks.com for upcoming trading sessions.

Clean energy is gaining traction as technology advances. Trillions are being invested in initiatives like solar power and hydrogen fuel cells. Learn about 5 clean energy stocks poised for growth in the free report “Nuclear to Solar: 5 Stocks Powering the Future.”



Read more at Nasdaq: Gilead Sciences (GILD) Stock Moves -0.57%: What You Should Know